重排肿瘤转染（RET）融合阳性在非小细胞肺癌（NSCLC）中发生的比例约为2％。这种突变通常预示着转移风险和恶性预后，并且目前主流疗法对患者的效益有限。Pralsetinib和Selpercatinib是针对RET突变肿瘤的选择性RET抑制剂，已获得美国食品药品监督管理局批准用于治疗融合阳性RET的肿瘤。其用于治疗NSCLC的I/II期临床试验结果已经发表。然而，选择性RET抑制剂对RET融合阳性NSCLC的临床效果存在争议。目的进行荟萃分析，研究选择性RET抑制剂在治疗RET融合阳性NSCLC中的疗效和安全性。 方法在Pubmed、Cochrane图书馆、Embase和Web of Science中搜索合格的文献。结果包括客观缓解率（ORR）、中位无进展生存期（mPFS）、疾病控制率（DCR）、颅内ORR和不良事件。使用Stata 15.1软件分析数据。结果本荟萃分析纳入了总共8个研究。综合结果显示，选择性RET抑制剂治疗患者的ORR为67％（95％可信区间：0.64至0.70，P <0.01），DCR为92％（95％CI：0.91-0.94，P <0.01），mPFS为16.09个月（95％CI：11.66-20.52，P <0.01）。对于接受RET突变治疗的患者，颅内ORR为86％（95％CI：0.74～0.96，P <0.01）。与未接受治疗的患者相比，未接受治疗的患者的ORR更有效[HR = 0.44（95％CI：0.35-0.56，P <0.01）]。主要不良事件（3-4级）为中性粒细胞减少（13％）和贫血（13％）。 结论选择性RET抑制剂Pralsetinib和Selpercatinib在RET融合阳性NSCLC上显示出良好效果，不良事件发生率低。©2023. 作者 。

Rearranged during transfection (RET) fusion-positive occurs in approximately 2% of non-small cell lung cancer (NSCLC). This mutation often predicts metastasis risk and poor prognosis, and current mainstream therapies provide limited patient benefit. Selective RET inhibitors Pralsetinib and Selpercatinib are targeted drugs approved by the US Food and Drug Administration for treating RET-mutated tumors. The phase I/II clinical trial results of their treatment of NSCLC have been published. However, the clinical effect of selective RET inhibitors on RET fusion-positive NSCLC remains controversial. Purpose Meta-analysis was performed to investigate the efficacy and safety of selective RET inhibitors in treating RET fusion-positive NSCLC. Methods Qualified literature was searched in Pubmed, Cochrane Library, Embase, and Web of Science. Outcomes included objective response rate (ORR), median progression-free survival (mPFS), disease control rate (DCR), intracranial ORR, and adverse events. Stata 15.1 software was used to analyze the data. Results A total of 8 studies were included in this meta-analysis. The combined results showed that the ORR of patients treated with selective RET inhibitors was 67% (95% confidence interval:0.64 to 0.70, P < 0.01), DCR was 92% (95%CI: 0.91-0.94, P < 0.01), the mPFS was 16.09 months (95%CI: 11.66-20.52, P < 0.01). In treated patients with RET mutation, the intracranial ORR was 86% (95%CI:0.74 ~ 0.96, P < 0.01). ORR in untreated patients was more effective than untreated patients [HR = 0.44 (95%CI: 0.35-0.56, P < 0.01)]. The major adverse events (grade 3-4) are neutropenia (13%) and anaemia (13%). Conclusions Selective RET inhibitors Pralsetinib and Selpercatinib have shown a good effect on RET fusion-positive NSCLC, with a low incidence of adverse events.© 2023. The Author(s).